Literature DB >> 22150596

Outpatient diagnostic of bladder tumours in flexible cystoscopes: evaluation of fluorescence-guided flexible cystoscopy and bladder biopsies.

Gregers G Hermann1, Karin Mogensen, Birgitte Grønkær Toft, Anders Glenthøj, Helle M Pedersen.   

Abstract

OBJECTIVE: The aim of this study was to evaluate photodynamic diagnosis (PDD) in flexible cystoscopes and the diagnostic quality of biopsies for diagnosis of non-muscle-invasive bladder cancer in the outpatients department (OPD).
MATERIAL AND METHODS: Seventy-three patients (aged 36-91 years) with recurrent non-muscle-invasive bladder cancer and a medium to high risk of recurrence had a flexible PDD cystoscopy performed in the OPD. The bladder was first examined in standard white light followed by PDD.
RESULTS: PDD was superior to white light diagnosis; PDD was positive in 16 patients (22%) where white light showed a normal bladder mucosa. Four of these patients had bladder tumour [4/73, 6%; two carcinoma in situ (CIS), two Ta]. The diagnosis was verified by transurethral resection of the bladder tumour in the operating room. In 20 patients (20/73, 27%) PDD identified additional tumour lesions that were not identified in white light (five CIS, 15 Ta). The false-positive detection rate of PDD was 0.41. False positivity was significantly reduced by simultaneous flex biopsies disproving malignancy. Biopsies were obtained from 57 patients and diagnosis of stage and grade were possible in 55 of these (97%). In two patients (4%) the tissue material was too small for diagnostic evaluation. Biopsies from 47 patients (83%) included muscularis mucosa and from 20 patients (35%) muscularis propria. In 30 patients all but one diagnosis from the OPD was confirmed by biopsy in rigid scopes in the operating room.
CONCLUSIONS: PDD-guided cystoscopy and bladder biopsy in flexible cystoscopes can be performed in an OPD setting and with reliable results for diagnosis of tumour stage Ta, CIS and T1a bladder cancer.

Entities:  

Mesh:

Year:  2011        PMID: 22150596     DOI: 10.3109/00365599.2011.637954

Source DB:  PubMed          Journal:  Scand J Urol Nephrol        ISSN: 0036-5599


  5 in total

1.  Micro-cost analysis of single-use vs. reusable cystoscopy in a single-payer healthcare system.

Authors:  Jaehoon Kim; Bruce Gao; Naeem Bhojani; Kevin C Zorn; Bilal Chughtai; Dean S Elterman
Journal:  Can Urol Assoc J       Date:  2022-10       Impact factor: 2.052

2.  Therapeutic outcome of fluorescence cystoscopy guided transurethral resection in patients with non-muscle invasive bladder cancer: a meta-analysis of randomized controlled trials.

Authors:  Haichao Yuan; Jianguo Qiu; Liangren Liu; Shuo Zheng; Lu Yang; Zhenghua Liu; Chunxiao Pu; Jinhong Li; Qiang Wei; Ping Han
Journal:  PLoS One       Date:  2013-09-13       Impact factor: 3.240

3.  Diagnosis of bladder cancer from the voided urine specimens using multi-target fluorescence in situ hybridization.

Authors:  Zunfu Ke; Yuanhua Lai; Xudong Ma; Shuhua Lil; Wenhua Huang
Journal:  Oncol Lett       Date:  2013-12-09       Impact factor: 2.967

4.  Red patches during bladder cancer surveillance: to biopsy or not to biopsy?

Authors:  Ditte Drejer; Jørgen Bjerggaard Jensen; Richard T Bryan
Journal:  Transl Androl Urol       Date:  2018-04

5.  Can routine outpatient follow-up of patients with bladder cancer be improved? A multicenter prospective observational assessment of blue light flexible cystoscopy and fulguration.

Authors:  Reza Zare; Magnus Grabe; Gregers G Hermann; Per-Uno Malmström
Journal:  Res Rep Urol       Date:  2018-10-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.